Merck settles suit over Vytorin trial; India fines ex-Ranbaxy director for insider trading;

@FiercePharma: Pennsylvania appeals court affirms $45M in Prempro damages; Pfizer says it'll go to state supreme court. Report | Follow @FiercePharma

> Merck ($MRK) agreed to pay $5 million in attorneys' fees and tweak its corporate governance rules to settle a shareholder suit over the delayed Enhance trial results. Story

> Indian regulators fined a former Ranbaxy Laboratories director and his wife for insider trading in Orchid Chemicals & Pharmaceuticals in 2008. Report

> U.K. regulators will review Shire's ADHD remedy Venvanse, sold as Vyvanse in the U.S., which would be the first amphetamine-based drug for the disorder in the EU if approved. Article

> Using certain seizure drugs in combination with HIV fighters can cause the antivirals to fail or reduce the effectiveness of the epilepsy meds, a new study finds. Release

> Eye drug maker Ista Pharmaceuticals says it's looking for higher sales and profits in 2012, with revenue expected to hit $180 million to $195 million. News

> Insys Therapeutics won FDA approval for its cancer pain drug Subsys, a sublingual fentanyl spray. Release

> Almost 33% of U.K. patients don't fill their prescriptions, saying they didn't have time or didn't want to pay for it. Story

> Rodman & Renshaw started covering Amylin ($AMLN) stock with an "underperform" rating and an $8 price target. Item

Biotech News

@FierceBiotech: Bleak forecast puts Lilly's R&D game plan to the test. Will this change Lechleiter's approach? Article | Follow @FierceBiotech

@JohnCFierce: Germany's Apogenix raises 7.5ME for glioblastoma drug work. Release | Follow @JohnCFierce

@RyanMFierce: Here's my own take on @Quintiles new digital patient unit, with insights from the group's chief: Story | Follow @RyanMFierce

@FierceMedDev: FDA Orders Safety Evaluation of Vaginal Mesh--Bloomberg. Article | Follow @FierceMedDev

> Fast-growing Forma grabs $815M cancer discovery deal with Boehringer. News

> Bleak forecast puts Eli Lilly's ambitious R&D game plan to the test. More

> Merck spinout nails promising study on hep C vaccine. Story

Manufacturing News

> Novartis adds OTC drug plant to GMP fix list. News

> AZ starts work on record-setting plant in China. Item

> Report: Big Pharma finds Indian collaborations costly. Story

> Pharma fires, pollution targeted in India. More

> Hospira enters angry-investor phase of remediation. Article

> Expired-drug take vs. toss debate gets new vetting. Story

Vaccine News

> Study: Most girls who get HPV vax say they see need to practice safe sex. Item

> FDA approves Pfizer's Prevnar 13 for adults over 50. Article

> Argentina fines GSK $93K for Synflorix vaccine trial in which 14 babies died. News

And Finally... Missed some FDA guidance last year? in-Pharma Technologist rounds up 2011's documents. Report

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.